All articles tagged with #kras
Originally Published 5 months ago — by yahoo.com
A new off-the-shelf vaccine called ELI-002 2P shows promising results in clinical trials for treating pancreatic and colorectal cancers by targeting KRAS gene mutations, with many patients developing strong immune responses and extended survival times, offering hope for more effective cancer therapies.
Originally Published 5 months ago — by Euronews.com
An early study suggests that an off-the-shelf cancer vaccine targeting KRAS mutations may boost immune response and prolong survival in some pancreatic and bowel cancer patients, but larger studies are needed to confirm its effectiveness.
Originally Published 5 months ago — by Medical Xpress
UNC researchers have developed a novel 'two-in-one' molecule using inverted RNAi technology that can simultaneously silence two challenging cancer genes, KRAS and MYC, and deliver drugs to tumors, offering promising new treatment avenues for difficult cancers.
Originally Published 1 year ago — by UC San Francisco
UC San Francisco scientists have developed a targeted radiation therapy that combines a cancer drug with a radioactive antibody to selectively destroy cancer cells, minimizing damage to healthy tissue. This approach, which effectively eliminated lung and bladder tumors in mice, uses a drug to flag cancer cells and a radioactive antibody to deliver precise radiation, potentially overcoming tumor resistance. The team is working on adapting this method for broader patient use by developing antibodies that account for individual cellular differences.
Originally Published 2 years ago — by Nature.com
Researchers have created multiple global atlases of inhibitory allosteric communication in KRAS, a protein involved in signaling pathways and a known therapeutic target. By quantifying the impact of over 26,000 mutations on the folding and binding of KRAS, the study identified allosteric sites that can be targeted for inhibition. The central beta sheet of KRAS was found to be particularly effective in allosteric propagation, and multiple surface pockets were validated as allosterically active, including a distal pocket in the C-terminal lobe of the protein. This research provides insights into the regulatory and therapeutic potential of allosteric modulation in proteins.
Originally Published 2 years ago — by Endpoints News
Roche has published Phase I data on its KRAS G12C inhibitor in the New England Journal of Medicine, showcasing its potential as a monotherapy across various cancers. The study included 137 patients with non-small cell lung cancer, colorectal cancer, and other solid tumors, as Roche aims to catch up with and surpass competitors Amgen and Mirati in the KRAS race.